Patient self-management of oral anticoagulation with vitamin K antagonists in everyday practice: clinical outcomes in a single centre cohort after long-term follow-up

Table 5 Incidence of major complications in different models of anticoagulant therapy in real world in patients with mechanical heart valves

							Incidence of major complications (% pt-ys)
Author	Year	Drug	N	Mean age (years)	Total follow-up (pt-ys)	Mean follow-up (years)	Haemorrhagic	Thrombotic	Total^b	Mortality
PSM of VKA
Mair [49]	2012	VKA	160	61.1	1376	8.6	2.2	0.6	2.8^a	0.3^a
Nagler [8]^b	2014	VKA	356	55.0	1530^a	4.3	0.4	1.5	1.9^a	1.0
Christensen [50]	2016	VKA	615	57.2	2685	7.1	1.1	1.6	2.7^a	1.1
*Our study*	2018	VKA	465	58.7	3236	7.0	1.3	1.1	2.4	1.8
Conventional management of VKA in highly specialized centres
Wieloch [23]	2011	VKA	597	67	519	0.9^a	2.3	2.7	5.0^a	NR
Sjöegren [24]	2015	VKA	6997	66.1	19592^a	2.8^a	3.4	1.5	4.9^a	NR
Christensen [50]	2016	VKA	3075	57.0	13,026	6.7	1.4	2.0	3.4	2.5
Grzymala [51]	2017	VKA	3831	63.3	18,022	4.7^a	3.1	1.4	4.5	2.4
Conventional management of VKA
Mair [49]	2012	VKA	260	66.3	2236	8.6	2.7	1.7	4.4^a	1.9^a

Data from Wieloch et al [23] and Sjöegren et al [24] relates to patients suffering from “heart valve disease”. We assume that the majority of them must be mechanical valves
^a Approximated value; NR not reported
^b Total major complications were approximated as the sum of haemorrhagic plus thromboembolic, if not explicitly given in the publication

ISSN: 1471-2261